Rintatolimod

N/A

Report date: 2023/04/03 15:36:04
NMEFirst In Class

Base Information

Drug NameRintatolimod
Drug Alias NameMismatched double-stranded RNA安普利近Poly I:polyC12UPoly I:Poly C12Upoly(I) poly(C12,U) +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 3 agonists
TargetsToll like receptor 3
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeOvarian NeoplasmsPancreatic Neoplasms +[12] 
Global Approved IndicationsFatigue Syndrome, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryArgentina
Original Approved Date2017/01/01
Country/TerritoryUnited StatesArgentina
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHemispherx Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAim Immunotech IncSmoore International Holdings LtdHemispherx Biopharma Inc
Inactive CompaniesRoswell Park Cancer InstituteNational Cancer InstituteUniversity Of Washington +[4] 
Active IndicationsPost-Acute COVID-19 SyndromeFatigue Syndrome, Chronic
Inactive IndicationsOvarian NeoplasmsPancreatic NeoplasmsColorectal Neoplasms +[10] 

Other Information

ATC CodeL03A
Related LinksWikipediaKEGG